Based on the measurements of operating efficiency obtained from Veracyte's historical financial statements, Veracyte is performing exceptionally good at this time. It has a great odds to report excellent financial results in April. At this time, Veracyte's Net Receivables is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 86.9 K in 2025, despite the fact that Retained Earnings are likely to grow to (421.8 M). Key indicators impacting Veracyte's financial strength include:
The essential information of the day-to-day investment outlook for Veracyte includes many different criteria found on its balance sheet. An individual investor should monitor Veracyte's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Veracyte.
Please note, the imprecision that can be found in Veracyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Veracyte. Check Veracyte's Beneish M Score to see the likelihood of Veracyte's management manipulating its earnings.
Veracyte Stock Summary
Veracyte competes with Crinetics Pharmaceuticals, Viridian Therapeutics, Cytokinetics, Structure Therapeutics, and Kura Oncology. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Veracyte's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Veracyte's current stock value. Our valuation model uses many indicators to compare Veracyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Veracyte competition to find correlations between indicators driving Veracyte's intrinsic value. More Info.
Veracyte is rated second in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Veracyte is roughly 1.57 . At this time, Veracyte's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Veracyte by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Veracyte Systematic Risk
Veracyte's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Veracyte volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Veracyte correlated with the market. If Beta is less than 0 Veracyte generally moves in the opposite direction as compared to the market. If Veracyte Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Veracyte is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Veracyte is generally in the same direction as the market. If Beta > 1 Veracyte moves generally in the same direction as, but more than the movement of the benchmark.
Veracyte Thematic Clasifications
Veracyte is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Veracyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Veracyte's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Veracyte growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Veracyte help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Veracyte. We use our internally-developed statistical techniques to arrive at the intrinsic value of Veracyte based on widely used predictive technical indicators. In general, we focus on analyzing Veracyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Veracyte's daily price indicators and compare them against related drivers.
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.